Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,308.60GBp
19 Feb 2018
Change (% chg)

-10.00 (-0.76%)
Prev Close
1,318.60
Open
1,324.00
Day's High
1,324.60
Day's Low
1,303.80
Volume
4,353,589
Avg. Vol
11,067,590
52-wk High
1,724.50
52-wk Low
1,235.20

Latest Key Developments (Source: Significant Developments)

Glaxosmithkline ‍Receives European Approval For Expanded Indication For Fluarix Tetra For Ages Six Months And Older​
Thursday, 15 Feb 2018 06:08am EST 

Feb 15 (Reuters) - Glaxosmithkline Plc ::‍RECEIVES EUROPEAN APPROVAL FOR EXPANDED INDICATION FOR FLUARIX TETRA (INFLUENZA VACCINE) FOR AGES SIX MONTHS AND OLDER​.  Full Article

Glaxosmithkline Submits Landmark Impact Data To European Medicines Agency To Support Expanded Label For Trelegy Ellipta​
Wednesday, 14 Feb 2018 04:00am EST 

Feb 14 (Reuters) - Glaxosmithkline Plc ::‍GSK SUBMITS LANDMARK IMPACT DATA TO EUROPEAN MEDICINES AGENCY TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA​.  Full Article

GlaxoSmithKline Says ‍ViiV Healthcare Launches New Two-Drug HIV Study
Thursday, 8 Feb 2018 02:00am EST 

Feb 8 (Reuters) - Glaxosmithkline Plc ::‍VIIV HEALTHCARE LAUNCHES EIGHTH PHASE III STUDY IN TWO-DRUG REGIMEN PROGRAMME FOR HIV-1 TREATMENT​.‍TANGO WILL SEEK TO ENROL APPROXIMATELY 550 ADULTS WITH HIV-1, FROM CLINICAL TRIAL SITES IN NORTH AMERICA, EUROPE, AUSTRALIA, AND JAPAN​.EXPECTS ‍RESULTS OF TANGO IN 2019.STUDY TO INVESTIGATE DOLUTEGRAVIR AND LAMIVUDINE IN PATIENTS WITH HIV WHO HAVE ACHIEVED VIRAL SUPPRESSION ON TENOFOVIR ALAFENAMIDE FUMARATE-BASED REGIMEN​.  Full Article

GSK's ViiV Healthcare Says Filed Patent Infringement Litigation Against Gilead Sciences
Thursday, 8 Feb 2018 02:00am EST 

Feb 8 (Reuters) - Glaxosmithkline Plc ::VIIV FILES PATENT INFRINGEMENT LITIGATION.GLAXOSMITHKLINE PLC - VIIV ‍ANNOUNCED IT FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN UNITED STATES AND CANADA​.  Full Article

ViiV Healthcare files patent infringement litigation against Gilead Sciences
Wednesday, 7 Feb 2018 04:15pm EST 

Feb 7 (Reuters) - :VIIV HEALTHCARE FILES PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR.VIIV HEALTHCARE - FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN THE UNITED STATES AND CANADA.VIIV HEALTHCARE - WILL SEEK TO PROVE THAT GILEAD'S TRIPLE COMBINATION HIV DRUG INFRINGES CO'S PATENT COVERING DOLUTEGRAVIR AND MANY OTHER COMPOUNDS.VIIV HEALTHCARE - VIIV HEALTHCARE WILL SEEK FINANCIAL REDRESS FOR PATENT INFRINGEMENT.  Full Article

GSK CEO says will take serious look at major consumer health assets
Wednesday, 7 Feb 2018 07:00am EST 

Feb 7 (Reuters) - Glaxosmithkline CEO Emma Walmsley tells reporters::CEO SAYS OBVIOUSLY EXPECTING MORE COMPETITION IN HIV THIS YEAR.CEO SAYS FIRST PRIORITY IS PHARMA RESEARCH AND DEVELOPMENT, WHICH COULD INCLUDE EARLY-STAGE DRUG DEALS.CEO SAYS NEXT PRIORITY IS CONSUMER PUT FROM NOVARTIS, IF IT COMES.CEO SAYS NO COMMENT ON PFIZER CONSUMER HEALTHCARE AUCTION BUT SHOULD EXPECT GSK TO TAKE SERIOUS LOOK AT MAJOR CONSUMER ASSETS.CEO SAYS BIG CONSUMER HEALTH DEAL 'NOT A NEED TO DO'.CEO SAYS BELIEVES SHINGRIX WILL BE BIGGEST VACCINE FOR GSK OVER MEDIUM TO LONG TERM.CEO SAYS 'WE KNOW DIVIDEND MATTERS TO OUR SHAREHOLDERS'.CEO SAYS MOST IMPORTANT THING ON BREXIT IS TO GET A TRANSITION PERIOD OF AT LEAST 2 YEARS, SECURED BY APRIL 2018.CEO SAYS ON BREXIT INDUSTRY NEEDS MUTUAL RECOGNITION, CLOSE WORK WITH EMA, MINIMAL TRADE FRICTION, CONTINUED RESEARCH AND DEVELOPMENT COLLABORATION WITH EU.  Full Article

GSK Says Bexsero Gets Breakthrough Therapy Designation From U.S. FDA​
Wednesday, 7 Feb 2018 04:04am EST 

Feb 7 (Reuters) - Glaxosmithkline Plc ::GSK'S BEXSERO FDA BREAKTHROUGH THERAPY DESIGNATION.GSK-BEXSERO GETS BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR PREVENTION OF INVASIVE MENINGOCOCCAL DISEASE IN CHILDREN AGED 2-10 YRS ​.  Full Article

GSK Receives FDA Approval For Expanded Indication For Fluarix
Friday, 12 Jan 2018 08:00am EST 

Jan 12 (Reuters) - Glaxosmithkline Plc ::GSK RECEIVES FDA APPROVAL FOR EXPANDED INDICATION FOR FLUARIX® QUADRIVALENT (INFLUENZA VACCINE) FOR PERSONS 6 MONTHS AND OLDER.  Full Article

GSK CEO Says No Expected Dividend Increase In Near Term
Tuesday, 9 Jan 2018 02:07pm EST 

Jan 9 (Reuters) - Glaxosmithkline Plc ::GSK CEO SAYS WILL TAKE TIME TO BUILD REIMBURSEMENT FOR SHINGRIX SHINGLES VACCINE.GSK CEO SAYS HAS NO DOUBT SHINGRIX CAN BE COMPANY'S MOST LUCRATIVE VACCINE.GSK CEO SAYS NO CHANGE TO DIVIDEND POLICY LAID OUT LAST YEAR.GSK CEO SAYS NO EXPECTED DIVIDEND INCREASE IN NEAR TERM.GSK CEO SAYS HAVING A LOOK AT PFIZER CONSUMER BUSINESS; WE DON'T NEED IT, WOULDN'T OVERPAY FOR IT.  Full Article

GlaxoSmithkLine Acquires Further 26 Pct Stake In Glaxo Saudi Arabia
Monday, 18 Dec 2017 04:19am EST 

Dec 18 (Reuters) - GLAXOSMITHKLINE ::ACQUIRES ADDITIONAL 26 PERCENT STAKE IN GLAXO SAUDI ARABIA LIMITED‍​.INTENDS TO EXPAND PRODUCTION OF JEDDAH MANUFACTURE SITE BY 30 PERCENT IN NEXT 3 YEARS WITH MORE INVESTMENTS TO BE DONE BY 2020‍​.SAYS "ACQUISITION IS COMING ON TOP OF MORE THAN SAR 900 MILLION THAT GSK IS INVESTING IN ITS OPERATION IN SAUDI OVER NEXT 3 YEARS‍​".SAYS "BY INCREASING STAKE IN GSAL, GSK REITERATES COMMITMENT TO SUPPORT SAUDI GOVERNMENT PLANS TO DIVERSIFY ECONOMY ‍".  Full Article

BRIEF-Glaxosmithkline ‍Receives European Approval For Expanded Indication For Fluarix Tetra For Ages Six Months And Older​

* ‍RECEIVES EUROPEAN APPROVAL FOR EXPANDED INDICATION FOR FLUARIX TETRA (INFLUENZA VACCINE) FOR AGES SIX MONTHS AND OLDER​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)